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Abstract
Traumatic axonal injury (TAI) accounts for at least 35% of the morbidity and mortality in traumatic brain injury
(TBI) patients without space-occupying lesions. It is also believed to be a key determinant of adverse outcomes
such as cognitive dysfunction across the spectrum of TBI severity. Previous studies have shown that COG1410, a
synthetic peptide derived from the apolipoprotein E (apoE) receptor binding region, has anti-inflammatory
effects after experimental TBI, with improvements in cognitive recovery. However, the effects of COG1410 on
axonal injury following TBI are not known. The current study evaluated the effects of 1mg/kg daily COG1410
versus saline administered intravenously starting 30min after controlled cortical impact (CCI) injury on peri-
contusional TAI in young, wild-type C57BL6/J male mice. We found that COG1410 did not affect the number of
amyloid precursor protein (APP)-immunoreactive axonal varicosities in the pericontusional corpus callosum and
external capsule at 24 h, but reduced APP-immunoreactive varicosities by 31% at 3 days ( p = 0.0023), and 36% at
7 days ( p = 0.0009). COG1410 significantly reduced the number of Iba1-positive cells with activated microglial
morphology at all three time points by 21–30%. There was no effect of COG1410 on pericontusional white matter
volume or silver staining at any time point. This indicates a possible effect of COG1410 on delayed but not
immediate TAI. Future studies are needed to investigate the underlying mechanisms, therapeutic time window,
and physiological implications of this effect.
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Introduction
Neuronal cell death has receivedmuch attention in thefield of traumatic brain injury (TBI). However, traumatic
axonal injury (TAI), sometimes referred to as diffuse axonal
injury (DAI), is well known to be associated with TBI of all
types, ranging from mild to severe (Adams et al., 1989;
Blumbergs et al., 1995,1989; Smith et al., 2003; Strich,
1956,1961). TAI may be of crucial importance in determining
adverse outcomes such as cognitive dysfunction across the
spectrum of TBI severity (Buki and Povlishock, 2006; Gen-
narelli et al., 1982; Kraus et al., 2007; Lipton et al., 2009; Niogi
andMukherjee, 2010; Niogi et al., 2008a,2008b; Perlbarg et al.,
2009; Smith et al., 2000; Wang et al., 2008).
The pathophysiology of TBI is extremely complex. In the
past decades, several biochemical mechanisms involved in
TBI have been demonstrated, including cellular calcium ho-
meostasis, inflammation, apoptosis, free radical generation,
and lipid peroxidation (Werner and Engelhard, 2007). Multi-
ple pharmacological agents based on these mechanisms have
reached Phase III clinical trials after promising results of an-
imal testing. However, to date, all of them have failed to show
a therapeutic benefit, and some have produced worse out-
comes for acute or chronic treatment of TBI (Margulies and
Hicks, 2009; Narayan et al., 2002). Of note, relatively few of
the candidate therapeutics have demonstrated preclinical
efficacy in TAI (Buki et al., 1999; Fujita et al., 2011; Koizumi
and Povlishock, 1998; Oda et al., 2011; Mbye et al., 2008;
Okonkwo et al., 2003; Smith et al., 2003).
Genetic polymorphisms may play a role in the suscepti-
bility of a given individual to adverse outcomes following TBI
(Dardiotis et al., 2010). Apolipoprotein E polymorphisms
(APOE =gene, apoE =protein) are the most extensively stud-
ied genetic factor in neurotrauma research ( Jellinger et al.,
2001,2004; Sun and Jiang, 2008; Teasdale et al., 2005). In hu-
mans, apoE is the major apolipoprotein expressed in the brain
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and exists as three isoforms, designated E2, E3, and E4.Many
studies, including our previous clinical research, have
demonstrated that the presence of the APOEe4 allele pre-
disposes individuals to clinical deterioration in the acute
phase and poor long-term outcome ( Jiang et al., 2006; Sorbi
et al., 1995; Teasdale et al., 1997,2005; Zhou et al., 2008).
Under normal physiologic conditions, apoE serves as an
important mediator of cholesterol and lipid transport in the
brain. In response to injury, apoE may exert neuroprotective
effects via multiple mechanisms including antioxidant, anti-
inflammatory, anti-excitotoxic, and neurotrophic mecha-
nisms (Hatters et al., 2006; Verghese et al., 2011). Studies of
genetically modified mice further suggested that apoE
modulates the response to brain injury. For example, apoE-
deficient mice have exacerbated cerebral edema and worse
functional deficits than their wild-type counterparts after
acute closed head injury (Chen et al., 1997; Lynch et al.,
2002). The above observations suggest a role for apoE in
remodeling and modulating recovery in response to injury,
and indicate the potential of neuroprotective therapy based
on apoE. In fact, several studies have demonstrated that
exogenous administration of intrathecal apoE improved
outcomes of ischemic injury (Horsburgh et al., 2000; McA-
doo et al., 2005). However, apoE does not cross the blood–
brain barrier (BBB) in appreciable quantities (Linton et al.,
1991). Since this makes it unsuitable for systemic adminis-
tration, apoE itself would be of limited practical use in clin-
ical trials.
To attempt to harness the therapeutic potential of endog-
enous apoE, apoE-mimetic drugs have been developed that
retain the receptor-binding and effective functional charac-
teristics of the intact apoE holoprotein, while being modified
to cross the BBB. COG133, a peptide based on apoE amino
acid residues 133–149, has been reported to demonstrate
neuroprotective, antioxidant, anti-excitotoxic, and anti-
inflammatory properties in vitro and in vivo (Aono et al., 2003;
Laskowitz et al., 2001; Lynch et al., 2003,2005; McAdoo et al.,
2005; Misra et al., 2001). Subsequently, COG1410 was devel-
oped, composed of apoE residues 138–149, with aminoiso-
butyric acid (Aib) substitutions at positions 140 and 145
(Laskowitz et al., 2007). COG1410 reportedly retains most
of the properties of COG133, and expands the therapeutic
window to 120min post-experimental TBI. The effects of
COG1410 have been assessed based on vestibulomotor
function, microglial activation, neuronal cell death in the
hippocampus, and neurodegenerative pathology (Hoane
et al., 2009; James et al., 2009; Laskowitz et al., 2010;
Tukhovskaya et al., 2009).
However, to our knowledge, the effects of COG1410 on
axonal injury have not been reported. Although TAI is con-
sidered a major contributor to cognitive dysfunction in TBI
patients, and is a process potentially amenable to therapeutic
intervention, the precise effects of COG1410 on the axonal
damage seen following TBI are still unclear. In the current
study, we explored the effects of COG1410 when adminis-
tered following controlled cortical impact (CCI) injury on
pericontusional TAI. We found that COG1410 attenuated
amyloid precursor protein (APP) immunohistochemistry at
subacute (3 and 7 days), but not acute (1 day) time points after
injury. Pericontusional white matter microglial activation as
indicated by Iba1 immunohistochemistry was reduced by
COG1410 at all three time points.
Methods
In this study, all the following procedures were approved
by the Washington University Animal Studies Committee,
and are consistent with the National Institutes of Health
(NIH) guidelines for the care and use of animals.
Experimental TBI: Controlled cortical impact
For these experiments, a total of 45 8- to 10-week-old
C57BL/6J male mice ( Jackson Laboratory, Bar Harbor, ME)
weighing 18–23 g were used. Three separate groups of mice
were sacrificed at 24 h, 3 days, and 7 days after experimental
injury. For each time point, 5 mice received TBI + COG1410, 5
mice received TBI + saline, and 5 mice underwent sham in-
jury. This injury model was adapted from a previously de-
scribed experimental TBI method for mice (Brody et al., 2007).
Briefly, the mice were anesthetized using 5% isoflurane,
shaved, and then placed in a stereotaxic frame (MyNeuroLab,
St. Louis, MO). Throughout the surgery, the mice were pro-
vided with constant 2% isoflurane in room air. Using sterile
technique, a midline incision was made, and the scalp was
reflected to expose the skull. A 5-mm left lateral craniotomy
was performed using a motorized drill mounted to the ste-
reotactic arm, and centered at 2.7mm lateral from the midline
and 3mm anterior to the lambda. The skull was removed
without disrupting the underlying dura. The impact depth of
the stereotaxic device was set at 2.0mm. The impactor, em-
ploying a 3-mm-diameter rod tip, was then driven at a ve-
locity of 5m/sec with a dwell time of 100msec. This produces
a moderately severe contusion in the left sensorimotor cortex
and underlying hippocampus, with pronounced behavioral
deficits but virtually no mortality. The sham group consisted
of mice that received craniotomy but not cortical impact.
Following the injury, a plastic skull cap was secured over the
craniotomy and adhered to the skull using cyanoacrylate. The
skin incision was sutured. The mice were kept at 37C via a
rectal temperature probe and feedback temperature controller
throughout the duration of the surgery. The anesthetizedmice
were placed in an incubator (37C) until they recovered the
ability to ambulate.
Synthesis and administration of peptides
COG1410 was synthesized and kindly provided by Cog-
nosci (Research Triangle Park, NC) at a purity of 95%.
COG1410 is Ac-AS(Aib)LRKL(Aib)KRLLamide, which is de-
rived from apoE residues 138–149 with Aib substitutions at
positions 140 and 145. The peptide was reconstituted in a
sterile 0.9% saline solution at a concentration of 1mg/kg prior
to administration. The mice were randomly assigned to either
the COG1410 (1mg/kg IV) or vehicle (0.9% saline IV) groups.
Injections were given 30min following injury, and then every
24 h (3-day group and 7-day group) via tail vein infusion.
Infusions were performed under brief (< 5min), light iso-
flurane anesthesia (2%).
Histopathology
The mice were deeply anesthetized with an overdose of
isoflurane and were perfused intracardially with ice-cold
phosphate-buffered saline (PBS, pH 7.4) plus 0.3% heparin.
After sacrifice, the brains were carefully removed, fixed in 4%
paraformaldehyde for 24 h, and then equilibrated in 30%
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sucrose. Serial coronal slices 50lm thick were cut on a freez-
ingmicrotome. Two sets of sections spaced every 300 lmwere
mounted on glass slides and used for immunohistochemical
studies as described previously (Mac Donald et al., 2007a).
The controls underwent the same procedures. Briefly, all
sections werewashedwith Tris-buffered saline (TBS) between
applications of antibody solutions. Endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide in TBS
(10min). After blocking of nonspecific binding sites with 3%
normal goat serum (Sigma-Aldrich Chemie, Steinheim,
Germany) in TBS containing 0.25% Triton X (TBS-X) for
30min, the slides were incubated with primary antibodies
overnight at 4C. The following antibodies were used for
immunohistochemistry: polyclonal rabbit anti-b-APP (In-
vitrogen, Carlsbad, CA) in a 1:500 dilution, and polyclonal
rabbit anti-Iba1 antibody (Wako Chemicals USA, Richmond,
VA) in a 1:1000 dilution. The slides were developed with
biotinylated secondary antibodies. Bound antibodies were
visualized with the horseradish peroxidase method (ABC
Elite kit, PK6100; Vector Laboratories, Burlingame, CA) and
diaminobenzidine (DAB). The sections were mounted on
glass slides and allowed to dry. Once dry, the slides were
dipped for 1min each in 50%-70%-95%-95%-100% ethanol
solutions, followed by 4min each in xylene. Finally the slides
were cover-slipped with Cytoseal 60 (Richard-Allan Scien-
tific, Kalamazoo, MI) for stereological quantification. As a
control for background staining, control sections were treated
in the same manner, except TBS solution was substituted for
the primary antibodies. Negative controls included sections
from uninjured mice, and sections from injured mice with
omission of the primary antibodies. The positive controls for
APP staining were brain slices from PDAPP mice.
Silver staining was performed on a third set of sections to
visualize degenerating neuronal elements in the brain. Sec-
tions were processed with the FD NeuroSilver kit II (FD
NeuroTechnologies, Elicott City, MD), according to the
manufacturer’s instructions with modifications as in our
previous study (Shitaka et al., 2011). The modified protocol
was made more sensitive and resulted in slightly increased
background. For the quantification of degeneration in the
corpus callosum and external capsule, entire transverse sec-
tions were digitized with an image analysis system. NIH
ImageJ software was used to measure the optical density of
silver staining, as previously described (Shitaka et al., 2011).
Stereological quantification
Unbiased stereological methods were used to quantify the
numbers of APP-stained axonal varicosities and Iba1-stained
microglia cells per cubic millimeter in the region of the corpus
callosum and external capsule via StereoInvestigator version
8.2 software (MicroBrightField, Williston, VT) and a Nikon
(Tokyo, Japan) Eclipse E800microscope. All assessments were
made by a single investigator blinded to the injury status and
treatment regimens of the animals. The optical fractionator
technique was used to count a systematic random sample of
positively-stained axonal varicosities over the entire rostral to
caudal extent of the region of interest. Details of these ste-
reological methods have been previously described (Mac
Donald et al., 2007a,2007b; Shitaka et al., 2011; Tran et al.,
2011). In brief, for quantification of APP-stained axonal vari-
cosities and Iba1-stained microglia, the region of the corpus
callosum and external capsule from each coronal slice was
outlined at low power (4 · ), followed by systematic counts of
objects of interest at high power (60 · , oil immersion), of sites
within the counting region randomly chosen by the Stereo-
Investigator software. For quantification of APP, a 200· 200-
lm (24 h and 3d), or 100· 100lm (7 days) sampling grid, and
a 40 · 40-lm counting frame was used. Non-axonal DAB-
stained structures (e.g., DAB-positive red blood cells) were
not counted. For quantification of Iba1, a 180 · 180-lm sam-
pling grid and an 80 · 80-lm counting frame was used. A
dissector height of 15lmand guard zones of 2.5 lmwere used
for all measurements. Seven sections per mouse for each stain
were used for the stereological estimation.
Statistical analysis
All data were analyzed using Prism 5.0 software (Graph-
Pad Software, SanDiego, CA). The results are presented as the
mean – standard error of the mean (SEM) of 5 animals. There
was no evidence indicating significant deviations from the
normal distribution in any of the data sets ( p > 0.05 by Sha-
piro-Wilk tests). Therefore, for each type of quantitative data
(APP and Iba1 counts, silver staining density, and white
matter volume), a two-way analysis of variance (ANOVA)
was used. The factors were treatment group (COG1410 versus
saline), and time (1, 3, or 7 days after injury). Significant
main effects or interactions were subjected to post-hoc analysis
for independent samples. Pre-specified post-hoc comparisons
included COG1410 versus saline at each time point. A sig-
nificance level of p< 0.05 after Bonferroni correction for mul-
tiple comparisons was used for all statistical analyses. All
p values have been reported before correction for multiple
comparisons.
Results
Effect of COG1410 on APP immunohistochemistry
in pericontusional TAI
The pericontusional corpus callosum and external cap-
sule are among the white matter structures most substan-
tially affected in CCI (Hall et al., 2005; Mac Donald et al.,
2007a,2007b). To explore the effects of COG1410 on peri-
contusional TAI, we examined APP accumulation in the
corpus callosum and external capsule axonal fibers after
COG1410 treatment.
As reported previously, we found spheroidal APP accu-
mulations in pericontusional white matter of injured mice.
The ipsilateral corpus callosum and external capsule ap-
peared to have the most prominent APP accumulations
(Fig. 1). No such axonal APP staining was observed in unin-
jured (sham) controls (Fig. 1M). Although there were still
numerous APP-stained varicosities (Fig. 1E–L) in injuredmice
at 3 days and 7 days, the extent of APP staining was reduced
compared with 24 h after TBI (Fig. 1N).
We examined the effects of COG1410 or vehicle treatment
on injured mice up to 7 days after TBI. There appeared to be
no difference in the number of APP-stained varicosities in the
ipsilateral corpus callosum and external capsule between
groups at 24 h (Fig. 1B and D). However, there appeared to be
fewer APP-stained varicosities in the COG1410 group (Fig.
1H and L), comparedwith the saline group (Fig. 1F and J), at 3
days and 7 days.
2334 JIANG AND BRODY
Quantitative analyses of APP-immunoreactive varicosities
in these regions using stereology confirmed the qualitative
histological findings (Fig. 1N). In a two-way ANOVA, there
were significant main effects of treatment (F= 14.92, p= 0.0007),
and of time since injury (F= 140.8, p< 0.0001), without a sig-
nificant treatment· time interaction (F= 2.3, n.s.). In pre-
specified post-hoc testing, COG1410 treatmentwas found not to
affect the numbers of APP-stained varicosities in the ipsilateral
corpus callosum and external capsule at 24 h (Fig. 1N; p= 0.10
by two-sided Student’s t-test). However, there was an ap-
proximately 31% reduction in APP-immunoreactive varicosi-
ties in the COG1410-treated group at 3 days ( p= 0.0023), and a
36% reduction at 7 days ( p= 0.0009).
Effect of COG1410 on microglial activation in regions
of pericontusional TAI
The ipsilateral corpus callosum and external capsule ap-
peared to have prominent Iba1 immunoreactivity in cells with
morphological characteristics of activatedmicroglia following
CCI (Fig. 2A). Minimal Iba1 staining was observed in sham-
injured mice (Fig. 2B). Morphological criteria have been used
to distinguish among four sub-populations of Iba1-
immunoreactive cells in mice. All four were observed
following CCI, including resting ramified microglia with
spindle-shaped cell bodies and numerous long, thin, branched
processes (Fig. 2C), hypertrophic microglia with extended
thicker processes (Fig. 2D), bushy microglia with densely-
branched processes (Fig. 2E), and amoeboid microglia with
densely-labeled cell bodies and few processes (Fig. 2F). How-
ever, there were numerous cells for which an objective deter-
mination of morphological sub-population could not be made.
Therefore, quantitative analyses were based on total numbers
of Iba1-immunoreactive microglial cells (Shitaka et al., 2011).
We examined the effects of COG1410 versus vehicle treat-
ment on Iba1-immunoreactive cells in injured mice at 24 h, 3
days, and 7 days after TBI (Fig. 3). Overall, the numbers of
Iba1-immunoreactive cells in pericontusional white matter
were observed to increasewith time after TBI. At all three time
points, there appeared to be fewer Iba1-immunoreactive
FIG. 1. Reduction in delayed but not acute pericontusional axonal injury after controlled cortical impact traumatic brain
injury (CCI-TBI) after COG1410 treatment. (A–M) Micrographs of amyloid precursor protein (APP) immunoreactivity in
pericontusional white matter of injured (A–L) and sham (M) wild-type C57BL/6J mice. Separate groups of mice were
assessed at 24 h (A–D), 3 days (E–H), and 7 days (I–L) after injury. Scale bar in A applies also to panels C, E,G, I, and K. Scale
bar in B applies also to panels D, F, H, J, and L. (N) Stereological quantification of numbers of APP-immunoreactive
varicosities in the ipsilateral corpus callosum and external capsule of injured mice receiving either COG1410 or vehicle
treatment (*p = 0.0023; **p= 0.0009 by Student’s t-test).
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microglia in the ipsilateral corpus callosum and external
capsule of COG1410-treated mice (Fig. 3A–F).
Quantitative analyses of Iba1-immunoreactive microglial
cell counts in these regions using stereology confirmed the
qualitative histological findings. In a two-way ANOVA, there
were significant main effects of treatment (F = 33.47,
p < 0.0001), and of time since injury (F = 203.8, p< 0.0001),
without a significant treatment · time interaction (F = 1.6,
n.s.). In prespecified post-hoc testing, COG1410 treatment was
found to reduce the numbers of APP-stained varicosities in
the ipsilateral corpus callosum and external capsule at all
three time points compared to vehicle-treated mice (Fig. 3G).
The reduction was 30% at 24 h ( p= 0.0026), 24% at 3 days
( p= 0.003), and 21% at 7 days ( p = 0.013).
Effect of COG1410 on estimated volume
of the ipsilateral corpus callosum and external capsule
To explore the effect of COG1410 on the white matter at-
rophy, the volume of remaining ipsilateral corpus callosum
and external capsule (Fig. 4A–D) was estimated by the Ca-
valieri method. In a two-way ANOVA, there was no signifi-
cant main effect of treatment (F= 1.5, n.s.), a significant main
effect of time since injury (F = 22.7, p< 0.0001), and no signif-
icant treatment · time interaction (F= 0.1, n.s.). No differences
between COG1410 treatment and saline groups were found at
any time point in post-hoc testing. (Fig. 4E).
Effect of COG1410 on silver staining
Controlled cortical impact has been reported to cause
widespread silver-staining abnormalities (Hall et al., 2005).
While the exact nature of these silver-staining abnormalities
has not been determined, they have been suggested to reflect
protein aggregation and neurodegenerative processes
(Betarbet et al., 2000; Ross and Poirier, 2004). Here we con-
firmed that CCI in mice results in widespread silver staining
in the injured brain. Densitometric methods were used to
FIG. 2. Iba1 immunoreactivity in the ipsilateral corpus
callosum and external capsule after controlled cortical impact
traumatic brain injury (CCI-TBI). (A–B) Low-power micro-
graphs of Iba1 immunoreactivity in pericontusional white
matter of injured (A), sham (B), and wild-type C57BL/6J mice.
(C–F) High-power micrographs of Iba1-immunoreactive
microglia of various morphologies, including resting ramified
(C), hypertrophic (D), bushy (E), and amoeboid (F).
FIG. 3. Reduction in pericontusional Iba1-immunoreactive
microglia following controlled cortical impact traumatic
brain injury (CCI-TBI) after COG1410 treatment. (A–F) High
power micrographs of Iba1-immunoreactive microglia. Mice
were assessed at 24 h (A–B), 3 days (C–D), and 7 days (E–F)
after injury. (G) Stereological quantification of numbers of
Iba1-immunoreactive activated microglia in the ipsilateral
corpus callosum and external capsule of injured mice re-
ceiving either COG1410 or vehicle treatment (*p= 0.0026,
**p = 0.0030, ***p = 0.0132 by Student’s t-test).
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FIG. 4. The volume of the ipsilateral corpus callosum and external capsule were not affected by COG1410. (A–C) Whole-
slice images illustrating the region of interest tracing (dotted outlines) on a single slice in sham-injured mice (Sham, A), mice
treated with saline (TBI-saline, B), and injured mice treated with COG1410 (TBI-COG1410, C). Full three-dimensional vol-
umes were estimated using the Cavalieri method. (D) Low-power micrograph illustrating the region of interest. (E) Quan-
titative analysis of full three-dimensional volumes, estimated using the Cavalieri method across multiple slices. No significant
differences were found between the COG1410- and saline vehicle-treated groups ( p> 0.05).
FIG. 5. No effects of COG1410 on silver staining intensity were seen in the ipsilateral corpus callosum and external capsule
following controlled cortical impact (CCI). (A–B) Low-power micrographs of silver staining in injured mice treated with
saline (A), and COG1410 (B), at 7 days. (C) Densitometric methods were used to quantify the extent of silver staining in the
full three-dimensional white matter region of interest (the areas in the single-slice images outlined in dotted lines in panels A
and B). Silver staining intensity peaked at 3 days, but was no different between COG1410- and saline-treated mice at any time
point ( p > 0.05).
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quantify the extent of silver staining in the ipsilateral corpus
callosum and external capsule. We found that the peak in
silver-staining density occurred at 3 days. However, there
was no significant difference between the extent of silver
staining in the ipsilateral corpus callosum and external cap-
sule at any time point post-injury in the COG1410- and saline-
treated groups (Fig. 5, p> 0.05). In a two-way ANOVA, there
was no significant main effect of treatment (F= 0.4, n.s.), a
significant main effect of time since injury (F= 89.3, p< 0.0001),
and no significant treatment· time interaction (F= 0.2, n.s.). No
differences between COG1410 treatment the and saline groups
were found at any time point in post-hoc testing. Thus, post-
traumatic silver staining was unaffected by COG1410 at a
dosing regimen that reduced APP and Iba1 immunoreactivity.
Discussion
In summary, COG1410 reduced the number of APP-
immunoreactive axons at 3 days and 7 days after controlled
cortical impact in mice, but did not affect APP immunoreac-
tivity at 24 h. COG1410 reduced the number of pericontu-
sional white matter Iba1-positive cells with activated
microglial morphology at all three time points. COG1410 did
not have a detectable effect on silver staining or white matter
atrophy in pericontusional regions at any time point. This
provides some initial experimental evidence that COG1410
may have a beneficial effect on some aspects of pericontu-
sional traumatic axonal injury.
There are several possible interpretations of these results.
One is that COG1410 has no effect on initial pericontusional
TAI, but inhibits one or more forms of delayed secondary
pericontusional TAI. The reduction in Iba1-positive microglia
suggests that an inflammatory component may play a role in
this delayed secondary injury. Another interpretation is that
COG1410 accelerates the clearance of APP-immunoreactive
axonal varicosities or reduces delayed transport of APP to the
site of injury. A third is that COG1410 impairs the immuno-
histochemical identification of APP-immunoreactive injured
axons through other mechanisms (e.g., downregulating APP
production, enhancing clearance of APP, or otherwise re-
ducing APP immunoreactivity). The lack of effect on silver
staining raises the question of which markers of white matter
injury are most appropriate. Silver staining has been reported
to be sensitive to the potential benefits of preclinical candidate
therapeutics such as the free radical scavenger Tempol (Deng-
Bryant et al., 2008). Further experiments using other markers
of axonal injury such as neurofilament immunohistochemis-
try, diffusion tensor imaging, electron microscopy, and elec-
trophysiology, will be required to fully address the effects of
COG1410 on axonal injury. Thus it is not entirely clear whe-
ther COG1410 truly preserves pericontusional axonal health
following CCI.
The effects of COG1410 on Iba1-immunoreactive activated
microglia at all time points suggest an effect on the inflam-
matory response to injury, as has been reported previously
(Laskowitz et al., 2007). Inflammatory responses may con-
tribute to secondary injury cascades that promote continued
cellular destruction, but it also could play a key role in repair
and regeneration of the injury (Kelley et al., 2007; Namas et al.,
2009; Shein et al., 2008). It is not known whether persistent
microglial activation is beneficial, neutral, or harmful on the
whole. One hypothesis is that microglia have a harmful effect
on pericontusional axonal injury, and that reduction in the
microglial response is the proximal mechanism by which
COG1410 affects TAI. Additional interventions targeting mi-
croglia will be necessary to directly address this hypothesis
(Elliott et al., 2011; Grathwohl et al., 2009; Namas et al., 2009).
By analogy, minocycline, which may also inhibit microglial
activation, has been shown to improve outcomes in other
experimental injury models (Kim and Suh 2009). Future in-
vestigations specifically focused on microglial subclasses
(Kigerl et al., 2009) are required to address the various roles of
microglia.
We favor the hypothesis that the Iba1-immunoreactive cells
with activated microglial morphology in the pericontusional
white matter represent a response to axonal injury. Previous
studies have indicated that apoE can suppress glial activation
following stimulation with a variety of structurally-diverse
agents (Barger and Harmon, 1997; Laskowitz et al., 1997). It
has been demonstrated that apoE modulates the CNS in-
flammatory response by downregulating glial secretion of
inflammatory cytokines and neurotoxic mediators such as
nitric oxide (NO) and tumor necrosis factor-a (TNF-a) in vitro
(Laskowitz et al., 2001).
There are several limitations of the current study. First, the
effects of COG1410 have only been tested on one type of TAI,
pericontusional. In contrast, human TAI can be diffuse or
multifocal, associated with rapid angular (rotational) accel-
eration and deceleration of the brain. Therefore, an additional
axonal injury paradigm such as fluid percussion injury or
impact acceleration injury, which produces more diffuse ax-
onal injury, is needed to verify our findings.
Second, these studies have been carried out in wild-type
mice. Strain-matched mice with human APOE alleles
‘‘knocked in’’ to the mouse loci (Laskowitz et al., 2010; Sulli-
van et al., 1997) should be tested to explore the pharmaco-
genetic effects of COG1410 on axonal injury.
Third, the dose-response and therapeutic window follow-
ing injury for COG1410 have not been determined. In the
current study, COG1410 was first injected intravenously at
30min following injury. In clinical trials, first doses starting
6–12 h after injury are considered the earliest feasible times,
unless waiver of consent can be obtained. Furthermore,
COG1410 was dosed every 24 h. A pharmacokinetic study of
COG1410 has shown that the half-life of COG1410 is
13 – 5min in blood plasma following intravenous adminis-
tration (M. Vitek, unpublished data). However, the pharma-
cokinetics of COG1410 in the brain have not been described.
In conclusion, these findings indicate a possible protective
effect of COG1410 on delayed traumatic axonal injury in the
setting of controlled cortical impact TBI. However, several
questions remain, and further studies are needed to determine
whether COG1410 can be considered a well-validated pre-
clinical therapeutic agent.
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